Article abstract-We initiated a double-blind, placebo-controlled trial to test the efficacy and safety of branched-chain amino acids (BCAA) (L-leucine 12 g, L-isoleucine 6 g, and L-valine 6 g daily) in amyotrophic lateral sclerosis (ALS) patients. There was an excess mortality in subjects randomized to active treatment (24 BCAA, 13 placebo) when a total of 126 ALS patients had been recruited. This finding, associated with the lack of efficacy of BCAA (measured by comparing the disability scales in the two treatment groups), led the Data Monitoring Committee to require cessation of the trial.

Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure?

CHIO', Adriano;SCHIFFER, Davide;
1993

Abstract

Article abstract-We initiated a double-blind, placebo-controlled trial to test the efficacy and safety of branched-chain amino acids (BCAA) (L-leucine 12 g, L-isoleucine 6 g, and L-valine 6 g daily) in amyotrophic lateral sclerosis (ALS) patients. There was an excess mortality in subjects randomized to active treatment (24 BCAA, 13 placebo) when a total of 126 ALS patients had been recruited. This finding, associated with the lack of efficacy of BCAA (measured by comparing the disability scales in the two treatment groups), led the Data Monitoring Committee to require cessation of the trial.
43
2466
2470
Beghi E; Fiordelli E; Mora G; Mazzini L; Poloni M; Pinelli P; Testa D; Cornelio F; Leone M; Bottacchi E; Chio' A; Schiffer D; Magi S; Sabatelli M; Tonali P; Formica A; Berardelli A; Manfredi M; Cattich N; Ferrannini E; Livrea P; Coretti A; Huber R; Musicco M
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/108261
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 76
  • ???jsp.display-item.citation.isi??? 64
social impact